ArticleBiotechnology for biofuels2021
Efficient lactic acid production from dilute acid-pretreated lignocellulosic biomass by a synthetic consortium of engineered Pseudomonas putida and Bacillus coagulans.
Article in Biotechnology for biofuels, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 51 citations in OpenAlex.
- Integrated Physiological and Transcriptomic Analyses ofBiology · 2026Article
- Engineering artificial microbial consortia for efficient lactic acid fermentation from undetoxified hydrolysates: from induced niche succession in a dual Bacillus coagulans consortium to Pseudomonas putida-assisted system reinforcement.Biotechnology for biofuels and bioproducts · 2026Article
- Valorization of barley bagasse for lactic acid production using an enzymatic cocktail produced by Aspergillus brasiliensis.Archives of microbiology · 2026Article
- Cooperativity in microbial biotechnology: synthetic consortia as emerging metabolic engineering strategy for sustainable bioproduction.Frontiers in bioengineering and biotechnology · 2026Review
- UpgradingACS omega · 2025Article
- Cold Plasma Treatment Facilitated the Conversion of Lignin-Derived Aldehyde for Pseudomonas putida.Applied biochemistry and biotechnology · 2025Article
- Enhanced production of lactic acid from pretreated rice straw using co-cultivation of3 Biotech · 2024Article
- Isolation and Characterization of a Low-Temperature, Cellulose-Degrading Microbial Consortium from Northeastern China.Microorganisms · 2024Article
- Biological Valorization of Lignin-Derived Aromatics in Hydrolysate to Protocatechuic Acid by EngineeredMolecules (Basel, Switzerland) · 2024Article
- Top-down and bottom-up microbiome engineering approaches to enable biomanufacturing from waste biomass.Journal of industrial microbiology & biotechnology · 2024Review
- Microbial tolerance engineering for boosting lactic acid production from lignocellulose.Biotechnology for biofuels and bioproducts · 2023Review
- Microbial detoxification of lignocellulosic biomass hydrolysates: Biochemical and molecular aspects, challenges, exploits and future perspectives.Frontiers in bioengineering and biotechnology · 2022Review
- Unraveling the mechanism of furfural tolerance in engineeredFrontiers in microbiology · 2022Article
- A consolidated review of commercial-scale high-value products from lignocellulosic biomass.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLignocellulosic biomass is an attractive and sustainable alternative to petroleum-based feedstock for the production of a range of biochemicals, and pretreatment is generally regarded as indispensable for its biorefinery. However, various inhibitors that severely hinder the growth and fermentation of microorganisms are inevitably produced during the pretreatment of lignocellulose. Presently, there are few reports on a single microorganism that can detoxify or tolerate toxic mixtures of pretreated lignocellulose hydrolysate while effectively transforming sugar components into valuable compounds. Alternatively, microbial coculture provides a simpler and more efficacious way to realize this goal by distributing metabolic functions among different specialized strains.
resultsIn this study, a novel synthetic microbial consortium, which is composed of a responsible for detoxification bacterium engineered Pseudomonas putida KT2440 and a lactic acid production specialist Bacillus coagulans NL01, was developed to directly produce lactic acid from highly toxic lignocellulosic hydrolysate. The engineered P. putida with deletion of the sugar metabolism pathway was unable to consume the major fermentable sugars of lignocellulosic hydrolysate but exhibited great tolerance to 10 g/L sodium acetate, 5 g/L levulinic acid, 10 mM furfural and HMF as well as 2 g/L monophenol compound. In addition, the engineered strain rapidly removed diverse inhibitors of real hydrolysate. The degradation rate of organic acids (acetate, levulinic acid) and the conversion rate of furan aldehyde were both 100%, and the removal rate of most monoaromatic compounds remained at approximately 90%. With detoxification using engineered P. putida for 24 h, the 30% (v/v) hydrolysate was fermented to 35.8 g/L lactic acid by B. coagulans with a lactic acid yield of 0.8 g/g total sugars. Compared with that of the single culture of B. coagulans without lactic acid production, the fermentation performance of microbial coculture was significantly improved.
conclusionsThe microbial coculture system constructed in this study demonstrated the strong potential of the process for the biosynthesis of valuable products from lignocellulosic hydrolysates containing high concentrations of complex inhibitors by specifically recruiting consortia of robust microorganisms with desirable characteristics and also provided a feasible and attractive method for the bioconversion of lignocellulosic biomass to other value-added biochemicals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.